Behavioral
Bellin Memorial Hospital INC
Bellin Memorial Hospital INC was paid $19.80M by Medicaid between Jan 2019 and Dec 2024, across 289 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 24% of everything it billed.
33Billing provider infoBELLIN MEMORIAL HOSPITAL INC
GREEN BAY, WI 54301
GREEN BAY, WI 54301
33aNPI1033172390assigned 04/08/2006
33bProvider typeProfessional Counselor
28Total paid$19.80M
24GClaims938,793
24DCodes billed289
24AFirst – last monthJan 2019 – Dec 2024
Compared with peers
Next to other Professional Counselor providers in Wisconsin
Rank by total paid#1 of 303
Median peer was paid$11K
This provider vs. median1,736×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 4,502 | $96K | |
| 2020 | 79,762 | $2.38M | |
| 2021 | 163,047 | $3.79M | |
| 2022 | 220,473 | $4.26M | |
| 2023 | 257,422 | $4.79M | |
| 2024incomplete | 213,587 | $4.49M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 24% | 98,772 | 87,030 | $4.72M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 17% | 90,152 | 80,710 | $3.35M |
| J0585 | Injection, onabotulinumtoxina, 1 unit | 16% | 6,832 | 3,713 | $3.22M |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 2.1% | 4,775 | 4,251 | $411K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 1.8% | 5,627 | 5,457 | $364K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 1.8% | 5,642 | 5,353 | $349K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 1.7% | 3,845 | 3,682 | $334K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 1.6% | 3,237 | 2,971 | $310K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 1.6% | 4,839 | 4,720 | $310K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1.2% | 7,941 | 7,229 | $237K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.2% | 11,717 | 5,364 | $233K |
| 90960 | End-stage renal disease related services monthly, for patients 20 years and older, with 4 or more face-to-face visits | 1.1% | 4,856 | 3,556 | $224K |
277 more codes
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 1.1% | 2,992 | $210K |
| 80053 | Comprehensive metabolic panel | 1.0% | 23,899 | $199K |
| 64615 | <1% | 3,558 | $189K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 4,131 | $187K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 4,403 | $180K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 2,628 | $163K |
| 80061 | Lipid panel | <1% | 16,061 | $162K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 1,927 | $161K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 679 | $160K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 1,671 | $159K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 2,137 | $144K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 10,078 | $141K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 1,790 | $136K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 24,006 | $132K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 20,693 | $128K |
| 90686 | <1% | 11,875 | $112K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 8,216 | $104K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,707 | $102K |
| 3008F | <1% | 11,631 | $100K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 599 | $93K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 2,386 | $92K |
| 80050 | General health panel | <1% | 1,960 | $88K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 11,944 | $85K |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 2,107 | $85K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 4,186 | $85K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 15,751 | $81K |
| 90677 | <1% | 1,083 | $75K | |
| 99283 | Emergency room visit (moderate) | <1% | 1,958 | $74K |
| 36415 | Collection of venous blood by venipuncture | <1% | 57,317 | $73K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 2,034 | $72K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 6,341 | $71K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 561 | $65K |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 6,222 | $57K |
| 0002A | <1% | 1,663 | $57K | |
| 0001A | <1% | 1,816 | $56K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 290 | $56K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 190 | $52K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,522 | $50K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 4,203 | $50K |
| 73221 | <1% | 238 | $47K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 1,593 | $45K |
| 0240U | <1% | 1,397 | $43K | |
| 95886 | <1% | 720 | $43K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 309 | $41K |
| 99221 | <1% | 899 | $37K | |
| 76820 | <1% | 1,022 | $36K | |
| 99205 | Prolong outpt/office vis | <1% | 298 | $35K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 533 | $35K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 278 | $34K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,048 | $33K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 155 | $32K |
| 97161 | <1% | 578 | $31K | |
| 81001 | <1% | 11,776 | $30K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,440 | $30K |
| 73630 | <1% | 1,830 | $26K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,940 | $26K |
| 73564 | <1% | 1,283 | $24K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,681 | $24K |
| 81025 | <1% | 3,084 | $23K | |
| 20553 | <1% | 1,714 | $22K | |
| 87210 | <1% | 3,967 | $20K | |
| 0124A | <1% | 584 | $19K | |
| 73610 | <1% | 1,363 | $19K | |
| 87428 | <1% | 618 | $19K | |
| 97597 | <1% | 1,235 | $18K | |
| 72100 | <1% | 1,008 | $18K | |
| 0071A | <1% | 650 | $18K | |
| 74018 | <1% | 1,649 | $18K | |
| 92567 | <1% | 1,422 | $17K | |
| 0004A | <1% | 548 | $17K | |
| 76825 | <1% | 149 | $17K | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 663 | $16K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 131 | $15K |
| 90651 | <1% | 867 | $15K | |
| 85027 | <1% | 2,769 | $15K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,992 | $14K |
| 73130 | <1% | 882 | $14K | |
| 0072A | <1% | 508 | $13K | |
| 73030 | <1% | 1,037 | $13K | |
| 90672 | <1% | 620 | $13K | |
| 93325 | <1% | 438 | $12K | |
| 73110 | <1% | 807 | $12K | |
| 0054A | <1% | 400 | $12K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 28 | $11K |
| 90670 | <1% | 2,709 | $11K | |
| 97162 | <1% | 216 | $11K | |
| 90723 | <1% | 2,283 | $11K | |
| 90656 | <1% | 749 | $10K | |
| 86140 | <1% | 2,436 | $10K | |
| 90647 | <1% | 2,126 | $9K | |
| 43248 | <1% | 129 | $9K | |
| 95806 | <1% | 240 | $9K | |
| 0064A | <1% | 225 | $8K | |
| 0031A | <1% | 238 | $8K | |
| 90680 | <1% | 1,565 | $7K | |
| 99244 | Office or other outpatient consultation, moderate to high complexity | <1% | 71 | $7K |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 217 | $7K |
| 73140 | <1% | 573 | $7K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 34 | $6K |
| 73620 | <1% | 507 | $6K | |
| 82043 | <1% | 1,347 | $6K | |
| 0011A | <1% | 144 | $6K | |
| 90746 | <1% | 81 | $6K | |
| 82570 | <1% | 1,413 | $5K | |
| 90715 | <1% | 478 | $5K | |
| 73560 | <1% | 381 | $5K | |
| V5266 | Battery for use in hearing device | <1% | 518 | $5K |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 357 | $5K |
| 83735 | <1% | 912 | $5K | |
| 93244 | <1% | 413 | $5K | |
| 0134A | <1% | 146 | $5K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 1,360 | $5K |
| 91320 | <1% | 49 | $5K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 12 | $5K |
| 0012A | <1% | 126 | $5K | |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | <1% | 144 | $4K |
| 90474 | <1% | 700 | $4K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 118 | $4K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 15 | $4K |
| 85018 | <1% | 1,737 | $4K | |
| 90961 | <1% | 165 | $4K | |
| 83690 | <1% | 655 | $4K | |
| 95251 | <1% | 292 | $3K | |
| 74019 | <1% | 278 | $3K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 85 | $3K |
| 99442 | <1% | 209 | $3K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 178 | $3K |
| 72141 | <1% | 14 | $3K | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 3,646 | $3K |
| 76830 | Ultrasound, transvaginal | <1% | 52 | $3K |
| 99309 | Subsequent nursing facility care, per day, low to moderate complexity | <1% | 94 | $3K |
| 76826 | <1% | 37 | $3K | |
| 95874 | <1% | 371 | $3K | |
| 17110 | <1% | 43 | $3K | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 225 | $3K |
| 92557 | <1% | 113 | $3K | |
| 87807 | <1% | 246 | $3K | |
| 90732 | <1% | 26 | $3K | |
| 85014 | <1% | 1,152 | $2K | |
| 90633 | <1% | 826 | $2K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 113 | $2K |
| 73562 | <1% | 179 | $2K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 15 | $2K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 62 | $2K |
| 90734 | <1% | 651 | $2K | |
| 85651 | <1% | 642 | $2K | |
| 73600 | <1% | 179 | $2K | |
| 95012 | <1% | 181 | $2K | |
| 95908 | <1% | 33 | $2K | |
| 82728 | <1% | 172 | $2K | |
| 0052A | <1% | 67 | $2K | |
| 93971 | <1% | 139 | $2K | |
| 90970 | <1% | 1,232 | $2K | |
| 36416 | <1% | 950 | $2K | |
| 80305 | <1% | 149 | $2K | |
| 73503 | <1% | 90 | $2K | |
| 99241 | <1% | 54 | $2K | |
| 64644 | <1% | 28 | $1K | |
| 99493 | <1% | 12 | $1K | |
| 90480 | <1% | 46 | $1K | |
| 99495 | <1% | 12 | $1K | |
| 99310 | Prolong nursin fac eval 15m | <1% | 13 | $1K |
| 96127 | <1% | 443 | $1K | |
| 76801 | <1% | 16 | $1K | |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 17 | $1K |
| 99460 | <1% | 12 | $1K | |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 41 | $1K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 95 | $1K |
| 93294 | <1% | 219 | $1K | |
| 11721 | <1% | 104 | $1K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,621 | $1K |
| 76827 | <1% | 18 | $1K | |
| 71101 | <1% | 66 | $998.54 | |
| 43235 | <1% | 16 | $994.13 | |
| 76828 | <1% | 19 | $947.92 | |
| 72040 | <1% | 54 | $942.52 | |
| 93295 | <1% | 70 | $929.23 | |
| 99441 | <1% | 111 | $906.49 | |
| 99152 | <1% | 59 | $904.04 | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 35 | $899.52 |
| 73502 | <1% | 62 | $897.51 | |
| 99308 | Subsequent nursing facility care, per day, straightforward | <1% | 54 | $891.61 |
| 76813 | <1% | 15 | $875.69 | |
| 90962 | <1% | 28 | $829.36 | |
| 73070 | <1% | 53 | $816.40 | |
| 90671 | <1% | 59 | $802.50 | |
| 99243 | <1% | 12 | $764.83 | |
| 99381 | <1% | 13 | $716.18 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 299 | $699.90 |
| 99223 | Prolong inpt eval add15 m | <1% | 15 | $688.14 |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 36 | $682.91 |
| 85610 | <1% | 223 | $599.36 | |
| A9573 | Injection, gadopiclenol, 1 ml | <1% | 49 | $538.03 |
| 93320 | <1% | 17 | $522.64 | |
| 0034A | <1% | 18 | $457.92 | |
| 90935 | Hemodialysis procedure with single evaluation by a physician | <1% | 17 | $455.65 |
| 94060 | <1% | 54 | $448.73 | |
| 90660 | <1% | 27 | $444.37 | |
| 90674 | <1% | 122 | $423.60 | |
| V5014 | Repair/modification of a hearing aid | <1% | 23 | $409.28 |
| 95117 | <1% | 94 | $382.11 | |
| 84484 | <1% | 39 | $355.47 | |
| 94010 | <1% | 15 | $354.67 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 17 | $354.20 |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 13 | $350.90 |
| Q3014 | Telehealth originating site facility fee | <1% | 14 | $327.66 |
| 20552 | <1% | 27 | $288.22 | |
| 90716 | <1% | 182 | $280.54 | |
| 93242 | <1% | 39 | $273.74 | |
| 94726 | <1% | 39 | $262.31 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 16 | $245.63 |
| 99443 | <1% | 12 | $244.38 | |
| 94729 | <1% | 65 | $235.81 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 32 | $219.61 |
| 72070 | <1% | 12 | $209.81 | |
| 69210 | <1% | 33 | $206.17 | |
| 80076 | <1% | 27 | $202.00 | |
| 73590 | <1% | 13 | $188.76 | |
| 87081 | <1% | 38 | $177.76 | |
| 83655 | <1% | 16 | $169.90 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 109 | $160.86 |
| 82947 | <1% | 38 | $125.93 | |
| 85379 | <1% | 12 | $112.29 | |
| 3044F | <1% | 6,486 | $100.00 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 49 | $98.99 |
| 82565 | <1% | 32 | $95.41 | |
| 81003 | <1% | 47 | $89.32 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 107 | $88.76 |
| 90707 | <1% | 218 | $77.16 | |
| 93018 | <1% | 13 | $56.00 | |
| 90688 | <1% | 21 | $52.96 | |
| 82950 | <1% | 13 | $52.25 | |
| 99421 | <1% | 30 | $46.80 | |
| 84550 | <1% | 12 | $44.38 | |
| 90710 | <1% | 12 | $39.82 | |
| 90696 | <1% | 39 | $39.82 | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 232 | $32.09 |
| 0298T | <1% | 15 | $10.70 | |
| G0008 | Administration of influenza virus vaccine | <1% | 26 | $7.00 |
| 3078F | <1% | 107,927 | $0.27 | |
| 3074F | <1% | 118,147 | $0.23 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 2,885 | $0.06 |
| 3075F | <1% | 7,718 | $0.05 | |
| 4010F | <1% | 11,926 | $0.03 | |
| 3077F | <1% | 2,664 | $0.01 | |
| 3079F | <1% | 15,321 | $0.01 | |
| 3080F | <1% | 1,558 | $0.01 | |
| 91312 | 0% | 487 | $0.00 | |
| 91300 | 0% | 4,230 | $0.00 | |
| 1160F | 0% | 925 | $0.00 | |
| 3050F | 0% | 2,897 | $0.00 | |
| 1159F | 0% | 1,047 | $0.00 | |
| 3046F | 0% | 509 | $0.00 | |
| 3051F | 0% | 679 | $0.00 | |
| 97602 | 0% | 83 | $0.00 | |
| 90700 | 0% | 49 | $0.00 | |
| 91313 | 0% | 133 | $0.00 | |
| 90473 | 0% | 198 | $0.00 | |
| 3062F | 0% | 15 | $0.00 | |
| G1010 | Clinical decision support mechanism stanson, as defined by the medicare appropriate use criteria program | 0% | 18 | $0.00 |
| 3048F | 0% | 11,125 | $0.00 | |
| 3049F | 0% | 3,854 | $0.00 | |
| 1126F | 0% | 500 | $0.00 | |
| 3061F | 0% | 1,455 | $0.00 | |
| 91303 | 0% | 266 | $0.00 | |
| 1125F | 0% | 364 | $0.00 | |
| 3060F | 0% | 401 | $0.00 | |
| 91306 | 0% | 224 | $0.00 | |
| 91305 | 0% | 623 | $0.00 | |
| 91307 | 0% | 1,231 | $0.00 | |
| 91301 | 0% | 354 | $0.00 | |
| 1157F | 0% | 125 | $0.00 | |
| 1111F | 0% | 74 | $0.00 | |
| 3052F | 0% | 146 | $0.00 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 31 | $0.00 |
| 99406 | 0% | 13 | $0.00 | |
| J3490 | Unclassified drugs | 0% | 29 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialENGEBOSE, ABBY (CREDENTIALING SPECIALIST)
| Provider | Location | Paid |
|---|---|---|
| Bellin Memorial Hospital INC. | Green Bay, WI | $29.28M |
| Oconto Hospital & Medical Center INC | Marinette, WI | $4.19M |
| Bellin Memorial Hospital INC | Algoma, WI | $249K |
| Bellin Memorial Hospital INC | Kewaunee, WI | $175K |
| Bellin Memorial Hospital INC | Brillion, WI | $22K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.